New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
08:01 EDTVRTXVertex reports improvement in lung function in proof-of-concept ivacaftor study
Vertex Pharmaceuticals announced the results of a two-part proof-of-concept study of ivacaftor in 24 people with cystic fibrosis who have a residual function mutation. The first part of the study evaluated ivacaftor, compared with placebo, in a two-week crossover design over two treatment cycles, and the second part of the study evaluated ivacaftor in an eight-week open-label design. In part one, a statistically significant improvement in mean absolute lung function was observed after treatment with ivacaftor for two weeks compared with placebo. In part two of the study, improvements in lung function were observed after eight weeks of treatment. In the study, ivacaftor was generally well-tolerated, and the most common adverse events in the treatment group were cough and respiratory tract infection. This proof-of-concept study was the first to evaluate the use of ivacaftor in multiple residual function mutations and is supported by in vitro observations that showed ivacaftor enhanced the function of the cystic fibrosis transmembrane conductance regulator protein in cells with residual function mutations. Based on these data, Vertex plans to initiate a larger Phase 3 study in people with residual function mutations that will evaluate longer-duration treatment with ivacaftor, pending discussions with regulatory authorities.
News For VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
07:50 EDTVRTXVertex reinstated with a Neutral at BofA/Merrill
Subscribe for More Information
September 29, 2014
09:09 EDTVRTXVertex was boosted by several catalysts, says RBC Capital
Subscribe for More Information
September 24, 2014
11:22 EDTVRTXOptions with increasing implied volatility
Subscribe for More Information
September 23, 2014
11:19 EDTVRTX Options with increasing implied volatility
Options with increasing implied volatility: HLF VRTX TRP CLX ETP VALE
07:55 EDTVRTXVertex should be bought into recent strength, says Wells Fargo
Subscribe for More Information
September 22, 2014
11:26 EDTVRTXOptions with increasing implied volatility
Options with increasing implied volatility: SHLD VRTX TRP AGNC
September 18, 2014
07:24 EDTVRTXVertex management to meet with Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use